introduction cryptocurrency Top stories

Yin Xiyue denied that emergency martial law was a civil strife. South Korean President Yin Xiyue made a speech today (December 12), denying that "emergency martial law" was a "civil strife". He once again criticized the opposition party for enslaving Congress and abusing the power to impeach public officials. Yin Xiyue said that both impeachment and investigation will face it head-on.The two-wheel drive robot industry in the policy market is welcoming the expansion period. The reporter was informed that many places have successively issued relevant policies for the development of the robot industry, planned development goals, and refined measures around improving basic innovation capabilities, accelerating the demonstration application of "robot+"innovation, and promoting the accelerated agglomeration of business entities to accelerate the innovation and development of the robot industry. Recently, Hangzhou released the Development Plan of Humanoid Robot Industry in Hangzhou (2024-2029). Chongqing, Nanjing, Sichuan Tianfu New District and other places have also issued relevant policies to promote the development of the robot industry, and based on the current situation and advantages of industrial development in various regions, promote the further development of the robot industry. Gao Chao, deputy general manager of CCID Consulting Advanced Manufacturing Research Center, said that the scale of China's robot industry is expected to grow to about 400 billion yuan during the Tenth Five-Year Plan period. While accelerating the overall development level of the robot industry, building an industrial innovation system and strengthening product application and promotion have also become the focus of multi-party efforts. Policy and market two-wheel drive have further opened up the development space for robot-related enterprises. (Economic Information Daily)CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.

South Korean President Yin Xiyue: The opposition party tried to paralyze the government. The opposition tried to get me out of office.Citic Jiantou: We are optimistic about the investment opportunities in the pharmaceutical industry in 2025, focusing on the opportunities of new increase and industry integration. Citic Jiantou Securities reported on December 11th that looking forward to 2025, the reform policy in the pharmaceutical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations on the whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.Zhong Xuegao's subsidiary was forced to execute 16.62 million yuan. According to the legal litigation information, recently, Zhongmao (Shanghai) Food Technology Co., Ltd. added a piece of information about the person to be executed, with the execution target of 16.62 million yuan. The enforcement court is the Yangpu District People's Court in Shanghai. Zhongmao (Shanghai) Food Technology Co., Ltd. was established in June 2020. The legal representative is Wang Keqin, with a registered capital of RMB 10 million, and it is wholly owned by Zhong Xuegao Food (Shanghai) Co., Ltd. Tianyan risk information shows that the company has more than 20 pieces of information about executed persons, and the total amount of execution exceeds 31.62 million yuan. In addition, there are also a number of consumption restriction orders, untrustworthy executed persons (Lao Lai) and final case information.

The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.CICC: Inflation in the United States may push the "hawks to cut interest rates". The CICC research report said that inflation data opened the door for the Fed to cut interest rates next week, but we also predicted that the "hawks to cut interest rates" will be staged next week, and the Fed may cut the guidance on interest rate cuts in the bitmap. We predict that the new bitmap will show that the total interest rate will be cut twice in 2025 (compared with four times before), and the federal funds rate will be lowered to a neutral level of 3.75% to 4% by the end of the second quarter of next year.List of A-share share repurchase: 16 companies disclosed the progress of repurchase, and on December 12, a total of 16 companies issued announcements related to share repurchase. Among them, four companies disclosed the stock repurchase plan for the first time, two companies' repurchase plans were approved by the shareholders' meeting, four companies disclosed the implementation progress of stock repurchase, and six companies' repurchase plans have been implemented. Judging from the initial disclosure of the repurchase plan, the amount of a company's stock repurchase plan on that day exceeded 10 million. Nanshan aluminum, Longzhu Science and Technology and Longzhu Science and Technology have the highest repurchase plans, and they plan to repurchase no more than 600 million yuan, 5,895,100 yuan and 1,171,000 yuan respectively. Judging from the repurchase plan passed by the shareholders' meeting, the repurchase plans of two companies exceeded 10 million on that day. Huaan Securities and Tongkun have the highest repurchase amount, with the planned repurchase not exceeding 200 million yuan and 51,966,700 yuan respectively. Judging from the implementation progress of repurchase, Shunluo Electronics, Shengquan Group and Hailiang have the highest repurchase amounts, with 9.009 million yuan, 3.8251 million yuan and 3.5187 million yuan respectively. Judging from the completed repurchase, the repurchase amount of four companies on that day exceeded 10 million. Chengda Pharmaceutical Co., Ltd., Jinshi Resources Co., Ltd. and Yingfangwei Co., Ltd. have completed the highest repurchase amounts, with 57,061,600 yuan, 53,158,000 yuan and 31,405,600 yuan respectively.